Kazia Therapeutics (KZIA)

• Market cap: $141M
• 1 day: 2.75%
• 5 days: -6.09%
• 1 month: -5.73%
• 3 months: -10.91%
• 6 months: 112.95%
• Year to date: 146.6%
• 1 year: 42.21%
• 5 years: -97.24%
• 10 years: -96.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Employees: 6